1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-020, NCT00689936
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: OHSU-HEM-05011-L, OHSU-210, NCT00245037
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PDX-009, NCT00481871
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 0 to 55
Sponsor: Other
Protocol IDs: 8717, NCT00673114
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VGFT-ST-0708, TCD10767, NCT00794417
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 265-103, NCT00975767
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 8 to 80
Sponsor: NHLBI
Protocol IDs: NHLBI-99-H-0050, NCT00003838
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: UCBT001, NCT00676806
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 11300A, NCT00683046
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPKC412D2201, NCT00782067
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 70
Sponsor: NCI, NHLBI
Protocol IDs: 606, U01 HL069294, NCT00864227
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 09-0713, NCT00914849
|
|
14.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 64 and under
Sponsor: Other
Protocol IDs: FHCRC-2212.00, NCI-2009-01244, NCT00968630
|
|
15.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0908-04; IUCRO-0256, NCT00975975
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 09-0679-04, NCT00997386
|
|
17.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 19 to 75
Sponsor: Other
Protocol IDs: 083-09, NCI-2009-01552, NCT01044745
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 26
Sponsor: Other
Protocol IDs: CHNY 525, AAAB2879, NCT01049854
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 65 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: MCC-16018, 108562, RV-MM-PI-0454, NCT01054144
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2007LS022, MT2006-01, 0701M00303, NCT00602693
|
|
21.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A8081001, NCT00585195
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1311002, SNX-5422-CLN1-002, NCT00595686
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 0C-07-6, NCT00630760
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP24534-07-101, NCT00660920
|
|
25.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: MDA-2007-0595, 2007-0595, 8109, NCT00678223
|
